

### Speakers



Alexandra Bauloye GSK, Belgium



Cheryl Chia BeiGene, The Netherlands



Dr Rainer Gnibl Government of Upper Bavaria, Germany



Savvas Koulouridas Fagron BV, The Netherlands



Dr Jens-Uwe Rengers JeRo Consulting, Switzerland



# Supply Chain Oversight

Supervision of the Pharmaceutical Supply Chain: Challenges and Opportunities

26/27 June 2025 | Barcelona, Spain



## Highlights

- Regulatory and legal Background
- Control and Oversight
- Import/ Export
- Contracts
- Necessary GMP Systems

## Objective

This 2-day Master Class brings together well-experienced experts to discuss the latest expectations and best practices for effective and efficient Supply Chain Oversight processes and how to get there.

## Background

There is a steady increase in dependence on global supply chains. Pharmaceutical companies not only source starting materials from all over the world, but also outsource manufacturing activities. The finished products are then distributed globally. These complex supply chains with different transport routes and manufacturing locations lead to major challenges in terms of maintaining the quality of materials, intermediates and medicinal products.

This has increased the risk of potential compliance and delivery problems, having a negative impact on a company's business and on the patient. Managing these supply chains and complying with GMP and GDP regulations require a comprehensive supply chain oversight with appropriate risk management measures.

The manufacturer, the Qualified Person (QP) but also the Responsible Person (RP) are primarily responsible for compliance with EU/EEA requirements:

- EU-GMP Annex 16, General principles: "The ultimate responsibility for the performance of a medicinal product over its lifetime, its safety, quality and efficacy, lies with the marketing authorisation holder (MAH)."
- EU-GMP Annex 16, 1.7.2: "The entire supply chain of the active substance and medicinal product up to the stage of certification is documented and available for the QP. This should include the manufacturing sites of the starting materials and packaging materials for the medicinal product and any other materials deemed critical through a risk assessment of the manufacturing process. The document should preferably be in the format of a comprehensive diagram..."

In the meantime, the competent authorities and inspectorates are also focusing on supply chain oversight processes; manufacturers and especially the marketing authorisation holder must know and control every level of the supply chain.

## Target Audience

QPs, RPs, Managers and Executives from pharmaceutical Quality and Supply Chain Units but also Senior Management, Business Executives and those involved in improving and controlling the pharmaceutical supply chain.

## Moderator

Wolfgang Schmitt (on behalf of ECA)

## Programme

#### Supply Chain Security: Regulatory Background

- Globalization: Challenge & risk also besides GMP/GDP
- Legal "oversight" requirements
- Responsibilities
- GMP-/GDP interface
- What do inspectors expect?
- Which are the essential tools?

#### Other legal Aspects to consider

- The EU Supply Chain Act and its consequences for pharmaceutical companies (Corporate Sustainability Due Diligence Directive (CSDDD)
- EMA recommendations to strengthen supply chains of critical medicinal products and other necessary actions to avoid drug shortages (MSSG, CMA)
- Strategies to avoid drug shortages

#### Supplier Control

- How to keep oversight over the pool of suppliers and brokers
- Ongoing Supplier Qualification
- Active Supply Chain tracking
- Filing second source suppliers for APIs

#### Useful Supply Chain Diagrams

- Initiation and creation
- Management and change control
- Examples

#### Master Data in the Supply Chain

- The broader framework on Master Data
- How will this impact the pharmaceutical supply chain?
- What does this mean for supply chain organisations?
- What does this mean for the quality organisations supporting the supply chain?
- Become a master of your data!

#### Import and Export: Regulatory Perspective in EU

- Annex 16: Supply chain focus
- Annex 21: Consequences
- Inspector's considerations on "best practices"

#### Contract Handling

- Different contracts in the Supply Chain (Forecasting, Supply, Quality/ Technical Agreement ...)
- Who needs to sign
- Contract handling: how to keep them up to date, how to avoid contradictions

#### Risk Management in the Supply Chain

- How to control quality, supply and business risks
- Drug shortages: requirements and mitigation
- Risk Register

#### Shipping Lane Risk Assessments

- Do we need them?
- What aspects of the shipping lane should be included?
- How much detail should be included?
- What actions might come out of the shipping lane assessment?

#### Social Event



On 26 June, you are cordially invited to a social event (city tour and Dinner). This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.



## Stay informed with the GMP Newsletters from ECA

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, simply scan the QR code on the right or visit www.gmp-compliance.org/gmp-newsletter



## Speakers



Alexandra Bauloye GSK, Belgium Senior Director

Alexandra Bauloye is Senior Director and Global Process Owner for Risk Management within GSC Quality.



Cheryl Chia BeiGene, The Netherlands Senior Director Distribution Quality

Cheryl Chia is Senior Director Distribution Quality. Before that she was cconsultant for GMP and GDP compliance in the pharmaceutical supply chain. Cheryl is also member of the Board of Directors of the European QP Association.



Dr Rainer Gnibl Government of Upper Bavaria, Germany Head of Inspectorate and GMP Inspector

Dr Rainer Gnibl is EU-GMP inspector in Germany and performs GMP inspections worldwide also on behalf of the European Medicines Agency (EMA). He is also member of the Board of Directors of the European QP Association.



Savvas Koulouridas Fagron BV, The Netherlands Global Innovations Director

Savvas Koulouridas is a lawyer in profession and has also worked as a consultant on pharmaceutical law (GMP regulations and Pharmaceutical Contracts).



Dr Jens-Uwe Rengers JeRo Consulting, Switzerland Consultant

Prior to the funding of his consultancy business, Jens-Uwe Rengers acted as General Manager at Akorn AG. Before that he was Director Quality and QP and held different other roles at Byk Gulden, Cytos Biotechnology AG and Siegfried Ltd.

n()
te in f
ıplet
se complete in fı
lease
<u>н</u>
Form
Reservation
serv
Re

26/27 June 2025, Barcelona, Spain Supply Chain Oversight

If the bill-to-address deviates from the specifiations on the right, please fill out here:

Purchase Order Number, if applicable Company Important: Please indicate your company's VAT ID Number Fitle, first name, surname E-Mail (Please fill in) Department Phone / Fax City Fax +49(0) 62 21/84 44 34

CONCEPT HEIDELBERG

P.O. Box 101764

D-69007 Heidelberg

GERMANY

for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal detawill not be disclosed to hird parties (see alone the privacy policy at http://www.gmp-compliance.org/leca.privacy.html). I note that I can ask for the modification, correction or deletion of my data at any Policy: By registering for this event, I accept the processing of ime via the contact form on this website.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receip to fayment will not be confirmed)! (As of July 2022). German law shall apply. Court of jurisdiction is Heidelberg. non-appearance. If you cannot take part, you have to inform us in cancellation fee will then be calculated according to the point of cellation or non-appearance. If you canr writing. The cancellation fee will then b time at which we receive your message.

responsible for discount airfare penalties or other costs incurred due to a cancellation. <mark>Terms of payment:</mark> Payable without deductions within 10 days after mportant: This is a binding registration and above fees are due in case of canreceipt of invoice.

or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees:

- Cancellation until 4 weeks prior to the conference 10 %,

- Cancellation until 3 weeks prior to the conference 25 %,

- Cancellation until 2 weeks prior to the conference 50 %,

- Cancellation within 2 weeks prior to the conference 100 %.

#### Date

Thursday, 26 June 2025, 9.00h - 17.00h (Registration and coffee 8.30h - 9.00h) Friday, 27 June 2025, 8.30h - 15.00h

#### Venue

Barceló Sants Hotel Plaça dels Països Catalans, s/n 08014 Barcelona, Spain +34 / 93 / 503 53 00 Phone Email sants@barcelo.com

#### Fees (per delegate, plus VAT)

ECA Members € 1,690 APIC Members € 1,790 Non-ECA Members € 1,890 EU GMP Inspectorates € 945

The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

#### Accomodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/POG when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

#### Registration

Via the attached reservation form, by e-mail or by fax – or search and register directly at www.gmp-compliance.org under the number 21608.

#### Presentation/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.

#### Conference language

The official conference language will be English.

#### Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

**CONCEPT HEIDELBERG** P.O.Box 10 17 64 69007 Heidelberg, Germany Phone +49(0)62 21/84 44-0 Fax +49(0)62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content please contact: Mr Wolfgang Schmitt (Director Operations) at +49 (0)62 21/84 44 39 or per e-mail at w.schmitt@concept-heidelberg.de

For questions regarding organisational details please contact: Ms Nicole Bach (Organisation Manager) at +49-62 21/84 44 22, or per e-mail at